The tolerable upper intake level set by the Institute of Medicine is 100 mg per day for adults, and the compounded dose is a small fraction of that
Current research is heavily focused on quantifying these benefits in conditions such as type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), and associated cardiovascular risk factors
Alternatives for special cases
The Main Factors That Affect Peptide Stability Peptides and related injectable medications can be sensitive to several environmental factors
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Notably, the long-term treatment with inhibitors of the GLP1degrading enzyme, dipeptidyl peptidase4 (DPP4), demonstrates improved muscle mass preservation in older age [17]